Altering the course of cataracts in diabetic rats.
A potent new aldose reductase (AR) inhibitor was effective in preventing cataractous changes in diabetic rats. Untreated diabetic rats developed early lens changes by 3 weeks and dense nuclear opacities by 6 to 9 weeks. In contrast, diabetic rats treated with the AR inhibitor showed no lens changes during the 5-month period of the experiment.